A5040773022- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Endometrial and Cervical Cancer Treatments
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Uterine Myomas and Treatments
- Ovarian cancer diagnosis and treatment
- Renal Transplantation Outcomes and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cervical Cancer and HPV Research
- Endometriosis Research and Treatment
- Polyomavirus and related diseases
- Antifungal resistance and susceptibility
- HIV/AIDS drug development and treatment
- Blood disorders and treatments
- Mesenchymal stem cell research
All India Institute of Medical Sciences
2012-2024
Northwestern University
2012-2023
All India Institute of Medical Sciences Bhopal
2012-2023
All India Institute of Medical Sciences Raipur
2012-2023
Indraprastha Apollo Hospitals
2019-2023
Northwestern Medicine
2006-2023
Freeman Hospital
2022
Institute of Medical Sciences
2021
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2005-2020
Satguru Partap Singh Hospital
2020
Bortezomib, a boronic acid dipeptide, is novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity.In this multicenter, open-label, nonrandomized, 2 trial, we enrolled 202 patients with relapsed myeloma was refractory the therapy they had received most recently. Patients 1.3 mg of bortezomib per square meter body-surface area twice weekly for weeks, followed by week without treatment, up eight cycles (24 weeks). In suboptimal response,...
Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, patients refractory disease.
To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment advanced multiple myeloma.Peripheral was assessed in two phase II studies 256 patients with relapsed and/or refractory myeloma treated 1.0 or 1.3 mg/m2 intravenous bolus on days 1, 4, 8, 11, every 21 days, for up to eight cycles. Peripheral evaluated at baseline, during study, after study by patient-reported symptoms using Functional Assessment Cancer Therapy Scale/Gynecologic...
Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These cells proliferate and produce monoclonal immunoglobulin in bone marrow causing skeletal damage, a hallmark multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, infections. The NCCN Myeloma Panel members have developed guidelines for management patients with various cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, systemic light chain...
The NCCN Guidelines for Multiple Myeloma provide recommendations diagnosis, evaluation, treatment, including supportive-care, and follow-up patients with myeloma. These Insights highlight the important updates/changes specific to myeloma therapy options in 2018 version of Guidelines.
The NCCN Guidelines for Multiple Myeloma provide recommendations diagnosis, workup, treatment, follow-up, and supportive care patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, multiple myeloma. These Insights highlight some the important updates changes in 1.2020 version Myeloma.
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to destruction and marrow failure.The American Cancer Society estimates 20,580 new cases MM will occur the United States 2009, including 11,680 men 8900 women, with an estimated 10,580 deaths. 1 The mean age affected individuals 62 years for (75% > 70 years) 61 women (79% years).The treatment has dramatically improved over past decade.The 5-year survival rate reported Surveillance...
Abstract BACKGROUND Bortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma, but its activity in patients with renal impairment not studied to date. METHODS Response rates, safety, and 20S were assessed relation baseline creatinine clearance (CrCl) among myeloma ( n = 256 patients) who treated bortezomib 2 Phase II trials. was administered by intravenous bolus on Days 1, 4, 8, 11 21‐day cycle at doses,...
Abstract BACKGROUND. Low voriconazole levels have been associated with a higher failure rate in patients confirmed fungal infections. METHODS. Steady‐state plasma trough were measured after at least 5 days of therapy 87 hematologic malignancies on 201 separate occasions (1–5 per patient; median, 2). Most (90%) had undergone allogeneic hematopoietic stem cell transplantation. The daily dose, administered 2 divided doses, was 200 mg (n = 4), 400 151), 500 20), 600 18), and 800 8);...
Summary Total Therapy 1, the first tandem autotransplant trial for newly diagnosed patients with multiple myeloma, was designed to increase frequency of complete response (CR) and thereby extend survival. With a median follow‐up 12 years, 62 231 initially enrolled are alive (17% at 15 years); 31 remain event free (7% years) including 16 94 (41%) that achieved CR. Currently less frequently had cytogenetic abnormalities (CAs) baseline ( P = 0·002), postenrolment < 0·001) relapse 0·004);...